Idiotype-specific CD4+ T cells eradicate disseminated myeloma

被引：17

作者：

Haabeth, O. A. ^{[1
,2
]}

Tveita, A. ^{[1
,2
]}

Fauskanger, M. ^{[1
,2
]}

Hennig, K. ^{[1
,2
]}

Hofgaard, P. O. ^{[2
,3
]}

Bogen, B. ^{[1
,2
,3
]}

机构：

[1] Univ Oslo, Ctr Immune Regulat, Dept Immunol, Inst Clin Med, Oslo, Norway

[2] Oslo Univ Hosp, Rikshosp, Oslo, Norway

[3] Univ Oslo, Inst Clin Med, Dept Immunol, KG Jebsen Ctr Influenza Vaccine Res, Oslo, Norway

来源：

LEUKEMIA | 2016年 / 30卷 / 05期

关键词：

IMMUNOSURVEILLANCE; EXPRESSION;

D O I：

10.1038/leu.2015.278

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1216 / 1220

页数：6

共 15 条

[1] Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma -: evaluation of T-cell responses by different read-out systems [J].

Abdalla, Amir Osman ;

Hansson, Lotta ;

Eriksson, Ingrid ;

Nasman-Glaser, Barbro ;

Rossmann, Eva D. ;

Rabbani, Hodjattallah ;

Mellstedt, Hakan ;

Osterborg, Anders .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01) :110-114

[2] IDIOTOPE-SPECIFIC T-CELL CLONES THAT RECOGNIZE SYNGENEIC IMMUNOGLOBULIN FRAGMENTS IN THE CONTEXT OF CLASS-II MOLECULES [J].

BOGEN, B ;

MALISSEN, B ;

HAAS, W .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1986, 16 (11) :1373-1378

[3] Primary antitumor immune response mediated by CD4+ T cells [J].

Corthay, A ;

Skovseth, DK ;

Lundin, KU ;

Rosjo, E ;

Omholt, H ;

Hofgaard, PO ;

Haraldsen, G ;

Bogen, B .

IMMUNITY, 2005, 22 (03) :371-383

[4] Secretion of Tumor-Specific Antigen by Myeloma Cells Is Required for Cancer Immunosurveillance by CD4+ T Cells [J].

Corthay, Alexandre ;

Lundin, Katrin U. ;

Lorvik, Kristina Berg ;

Hofgaard, Peter O. ;

Bogen, Bjarne .

CANCER RESEARCH, 2009, 69 (14) :5901-5907

[5] Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells [J].

Gattinoni, L ;

Finkelstein, SE ;

Klebanoff, CA ;

Antony, PA ;

Palmer, DC ;

Spiess, PJ ;

Hwang, LN ;

Yu, ZY ;

Wrzesinski, C ;

Heimann, DM ;

Surh, CD ;

Rosenberg, SA ;

Restifo, NP .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (07) :907-912

[6] Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells [J].

Ghosh, N ;

Gyory, I ;

Wright, G ;

Wood, J ;

Wright, KL .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (18) :15264-15268

[7] How do CD4+ T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? [J].

Haabeth, Ole Audun Werner ;

Tveita, Anders Aune ;

Fauskanger, Marte ;

Schjesvold, Fredrik ;

Lorvik, Kristina Berg ;

Hofgaard, Peter O. ;

Omholt, Hilde ;

Munthe, Ludvig A. ;

Dembic, Zlatko ;

Corthay, Alexandre ;

Bogen, Bjarne .

FRONTIERS IN IMMUNOLOGY, 2014, 5

[8] A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic Disease [J].

Hofgaard, Peter O. ;

Jodal, Henriette C. ;

Bommert, Kurt ;

Huard, Bertrand ;

Caers, Jo ;

Carlsen, Harald ;

Schwarzer, Rolf ;

Schuenemann, Nicole ;

Jundt, Franziska ;

Lindeberg, Mona M. ;

Bogen, Bjarne .

PLOS ONE, 2012, 7 (12)

[9] Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity [J].

Hong, S. ;

Li, H. ;

Qian, J. ;

Yang, J. ;

Lu, Y. ;

Yi, Q. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2012, 170 (02) :167-177

[10] Idiotype Vaccines for Human B-Cell Malignancies [J].

Inoges, S. ;

Lopez-Diaz de Cerio, A. ;

Soria, E. ;

Villanueva, H. ;

Pastor, F. ;

Bendandi, M. .

CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (03) :300-307

← 1 2 →